Evaluation of Posttreatment Eradication Testing Following Helicobacter pylori Therapy
Abstract
INTRODUCTION
In 2024, the American College of Gastroenterology updated its guidelines for Helicobacter pylori and now recommends utilizing optimized bismuth quadruple therapy in treatment naïve patients due to a rise in resistance in clarithromycin and levofloxacin therapies. It also emphasizes the importance of posttreatment eradication 4 weeks after treatment has been completed to confirm the infection was successfully eradicated. The authors' goal was to evaluate the rate and frequency of eradication testing to identify if there were opportunities to optimize therapy.
METHODS
This retrospective cohort study included adult patients of Kaiser Permanente Georgia who had completed H pylori treatment from August 31, 2024, to August 31, 2025. The primary objective of this study was to determine whether eradication testing was completed within the appropriate time frame, if the infection was successfully eradicated, and whether testing was performed. The secondary outcome identified which treatment regimens were being utilized and evaluated potential barriers to therapy, including adherence and allergy-related issues.
RESULTS
This cohort included 51 patients, with 54 confirmed cases of H pylori. Eradication testing was performed in 33 cases (61%) overall, with 27 cases (50%) completed within the designated time frame. Testing was not completed in 21 cases (39%), and 7 cases (13%) were completed but outside the required time frame.
CONCLUSION
Eradication testing was not completed…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 51 participants or records.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.